Criteria Caixa S.A.U. Takes Position in IQVIA Holdings Inc. $IQV

Criteria Caixa S.A.U. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 310,282 shares of the medical research company’s stock, valued at approximately $58,935,000. IQVIA comprises approximately 5.9% of Criteria Caixa S.A.U.’s investment portfolio, making the stock its 7th largest position. Criteria Caixa S.A.U. owned 0.18% of IQVIA at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. increased its stake in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of IQVIA in the 3rd quarter valued at approximately $36,000. Asset Dedication LLC boosted its stake in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC boosted its stake in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several recent analyst reports. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Finally, Citigroup reduced their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $229.13.

IQVIA Stock Up 1.1%

IQVIA stock opened at $164.78 on Friday. The company has a 50 day moving average of $201.58 and a 200-day moving average of $206.80. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The stock has a market capitalization of $27.96 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.59 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.